A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Clinical trial NCT06846671 · RECRUITING
Trial details
- NCT number
- NCT06846671
- Sponsor
- BeOne Medicines
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-10
- Primary completion
- 2028-05-15
- Enrollment
- 250
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.